Cellector biosciences Inc., an oncology-focused, clinical stage biotechnology company, announces the United States Patent and Trademark Office has granted a method of use of patent CLR124, the companies cancer imaging agent, which utilizes collectors proprietary phospholipids drug conjugate (PDC) delivery platform.

Importance of the patent

The recently issued patent, 9,579,406 titled “Phospholipids ether analogs as agent for detecting and locating cancer and method thereof “outlines the use of CLR124 in PET imaging to detect radiation –insensitive or chemo-therapy insensitive cancers and cancer metastases.

This patent further demonstrates the utility of our PDC delivery platform to effectively provide cancer targeting for both therapeutic and diagnostic oncologic payloads, potentially allowing for more effective treatment, regardless of the modality,” said Jim Caruso, president and CEO of Cellectar.  “We remain focused on developing our therapeutic assets, specifically CLR 131, for the treatment of multiple myeloma and other hematologic malignancies.  However, the potential of the platform provides significant opportunity in a variety of clinical applications.”

About phospholipids drug conjugates

Cellectors product candidate are built upon its patented cancer cell- targeting delivery and retention platform of optimized phospholipids ether –drug conjugates (PDC). The basis for selective tumor targeting of our PDC compound lies in the difference between plasma membrane of cancerous cell compared to those of normal cell. Cancer cells are highly enriched in lipid raft, which are glycolipoprotein micro domains of plasma membrane cells that contain high concentration of cholesterol and sphingolipid, and serve to organize cell surface and intracellular signaling molecules. PDC have been tested in more than 80 different xenograft model of cancer.

The company deliberately designed its phospholipids ether (PLE) carrier platform to be coupled with a variety of payloads to facilitate both therapeutic and diagnostic application.

About Collector Biosciences, Inc.

Cellector biosciences is developing phospholipids drug conjugates( PDC) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancer and cancer stem cells. Collectors PDC pipeline includes product candidate for cancer therapy and cancer diagnostic imaging. CLR 131, a cytotoxic radioisotope is currently being evaluated under an orphan drug designated Phase1 clinical study in patient with relapsed or refractory multiple myeloma. In addition the company plans to initiate a Phase2 clinical study to assess efficacy in a range of B-cell malignancies in first quarter of 2017. The company is also developing PDCs for targeted delivery of chemotherapeutics paclitaxel (CLR-1602-PTX), a preclinical stage product candidate, and plans to extend its PDC chemotherapeutic pipeline through both in house and collaborative R&D efforts.

This news release contains forward-looking statements.  You can identify these statements by our use of words such as “may,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “continue,” “plans,” or their negatives or cognates.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.

Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators’ ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.